Recent trials with monoclonal antibodies targeting amyloid-β (Aβ) in Alzheimer's disease
(AD) have sparked a renewed interest in disease-modifying therapies. Despite their …

The recent, controversial approval of antibody-based treatments for Alzheimer's disease
(AD) is fueling a heated debate on the molecular determinants of this condition. The …

Alzheimer's disease (AD) is a common cause of dementia characterized by
neurodegenerative dysregulations, cognitive impairments, and neuropsychiatric symptoms …

The need for regulatory approval of new therapies for the treatment of Alzheimer's disease—
a progressive neurodegenerative condition—has made the assessment of treatment efficacy …

Alzheimer's disease (AD) is a debilitating neurodegenerative condition characterized by
progressive cognitive decline and memory loss, affecting millions of people worldwide …

A hallmark of Alzheimer's disease (AD) are the proteinaceous aggregates formed by the
amyloid-beta peptide (Aβ) that is deposited inside the brain as amyloid plaques. The …

The amyloid cascade hypothesis as the etiological underpinning of Alzheimer's disease
(AD) is supported by a large body of literature, the most influential of which are genetic …

An absence of population-representative participant samples has limited research in healthy
brain aging. We highlight examples of what can be gained by enrolling more diverse …

Disputes about the scientific validity of the amyloid‐β hypothesis of Alzheimer's disease
have been held since the early 1990s, with little constructive progress made between …

The objective of this editorial is to advocate for minoritized individuals, as well as other
demographic groups who were under-represented in clinical trials of anti-amyloid …